While we observed impaired survival after trastuzumab in CCNE1-amplified gastric cancer compared with nonamplified gastric adenocarcinoma, surprisingly, we noted a trend toward improved survival after initiation of immunotherapy. This evidence concerns the gene CCNE1 and gastric adenocarcinoma.